Clinical trials in Stavanger – page 2

128 clinical trials in Stavanger, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in NorwayKliniske-Studier.no

Stavanger at a glance

128

clinical trials

Research sites2

Quick filters

128 trials in Stavanger

Open in trial search

Plasma cell myeloma refractory

Recruiting

InvestigationalNo placebo

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Janssen - Cilag International

Contact Research Centre

Neuroendocrine carcinoma

Recruiting

Registered drugNo placebo

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Fallopian tube cancer+2

Recruiting

Registered drugNo placebo

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Ovarian cancer

Recruiting

Registered drugNo placebo

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Ischaemic stroke

Recruiting

Registered drugNo placebo

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Investigational

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

Norway

Participants:18–64 years · 65+ years
Substances:BLEXIMENIB
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Endometrial cancer+1

Recruiting

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Db-1303
Sponsor:BioNTech SE

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

IgA nephropathy

Recruiting

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Norway

Participants:18–64 years · 65+ years
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Transitional cell carcinoma

Recruiting

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Endometrial cancer

Recruiting

Registered drugNo placebo

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Stavanger

What the registry says about research in the country

01 Respiratory Medicine

Research focusing on respiratory tract infections and breathing disorders, including studies on chronic wet cough in children and innovative treatments for asthma prevention.

Antibiotic efficacy in pediatric respiratory conditions
Viral respiratory infections management
Wheezing and bronchiolitis treatments

Studies evaluating new therapeutic approaches for both acute and chronic respiratory conditions.

02 Oncology Research

Comprehensive cancer studies exploring treatments for various types including breast cancer, lung cancer, and rare cancers.

Targeted therapies for lung cancer
Precision medicine in rare cancers
Prostate cancer biomarker studies

Focus on personalized treatment approaches and innovative therapeutic combinations.

03 Cardiovascular Medicine

Investigations into stroke prevention and cardiovascular disease management, with emphasis on new therapeutic agents.

Atrial fibrillation treatments
Atherosclerotic disease prevention
Acute ischemic stroke interventions

Studies aimed at reducing cardiovascular events and improving patient outcomes.

Back to Norway All countries